85 related articles for article (PubMed ID: 26122732)
1. Hypertension: A new therapeutic strategy for PAH.
Carney EF
Nat Rev Nephrol; 2015 Aug; 11(8):445. PubMed ID: 26122732
[No Abstract] [Full Text] [Related]
2. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Long L; Ormiston ML; Yang X; Southwood M; Gräf S; Machado RD; Mueller M; Kinzel B; Yung LM; Wilkinson JM; Moore SD; Drake KM; Aldred MA; Yu PB; Upton PD; Morrell NW
Nat Med; 2015 Jul; 21(7):777-85. PubMed ID: 26076038
[TBL] [Abstract][Full Text] [Related]
3. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Orriols M; Gomez-Puerto MC; Ten Dijke P
Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104
[TBL] [Abstract][Full Text] [Related]
4. Pathobiology of pulmonary hypertension.
Rabinovitch M
Annu Rev Pathol; 2007; 2():369-99. PubMed ID: 18039104
[TBL] [Abstract][Full Text] [Related]
5. Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications.
Michelakis ED
Circ Res; 2006 Feb; 98(2):172-5. PubMed ID: 16456109
[No Abstract] [Full Text] [Related]
6. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
[TBL] [Abstract][Full Text] [Related]
7. Severe pulmonary arterial hypertension: a forme fruste of cancer?
Humbert M; Hoeper MM
Am J Respir Crit Care Med; 2008 Sep; 178(6):551-2. PubMed ID: 18755928
[No Abstract] [Full Text] [Related]
8. Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children.
Hall S; Brogan P; Haworth SG; Klein N
Thorax; 2009 Sep; 64(9):778-83. PubMed ID: 19525266
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.
Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S
Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212
[TBL] [Abstract][Full Text] [Related]
10. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
Teichert-Kuliszewska K; Kutryk MJ; Kuliszewski MA; Karoubi G; Courtman DW; Zucco L; Granton J; Stewart DJ
Circ Res; 2006 Feb; 98(2):209-17. PubMed ID: 16357305
[TBL] [Abstract][Full Text] [Related]
11. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Wang Y; Zhang XH; Wang HL
Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
[TBL] [Abstract][Full Text] [Related]
12. Endothelial progenitor cells in pulmonary arterial hypertension.
Diller GP; Thum T; Wilkins MR; Wharton J
Trends Cardiovasc Med; 2010 Jan; 20(1):22-9. PubMed ID: 20685574
[TBL] [Abstract][Full Text] [Related]
13. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension.
Li M; Vattulainen S; Aho J; Orcholski M; Rojas V; Yuan K; Helenius M; Taimen P; Myllykangas S; De Jesus Perez V; Koskenvuo JW; Alastalo TP
Am J Respir Cell Mol Biol; 2014 Jun; 50(6):1118-28. PubMed ID: 24433082
[TBL] [Abstract][Full Text] [Related]
14. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension.
Zakrzewicz A; Hecker M; Marsh LM; Kwapiszewska G; Nejman B; Long L; Seeger W; Schermuly RT; Morrell NW; Morty RE; Eickelberg O
Circulation; 2007 Jun; 115(23):2957-68. PubMed ID: 17515463
[TBL] [Abstract][Full Text] [Related]
15. BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling.
Feng F; Harper RL; Reynolds PN
Respirology; 2016 Apr; 21(3):526-32. PubMed ID: 26689975
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary arterial hypertension: a look to the future.
Rubin LJ; Galiè N
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):89S-90S. PubMed ID: 15194184
[TBL] [Abstract][Full Text] [Related]
17. Pathology of pulmonary hypertension.
Tuder RM; Marecki JC; Richter A; Fijalkowska I; Flores S
Clin Chest Med; 2007 Mar; 28(1):23-42, vii. PubMed ID: 17338926
[TBL] [Abstract][Full Text] [Related]
18. BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.
Vengethasamy L; Hautefort A; Tielemans B; Belge C; Perros F; Verleden S; Fadel E; Van Raemdonck D; Delcroix M; Quarck R
Pflugers Arch; 2016 Nov; 468(11-12):1969-1983. PubMed ID: 27816994
[TBL] [Abstract][Full Text] [Related]
19. Cellular and molecular pathobiology of pulmonary hypertension conference summary.
Rabinovitch M
Chest; 2005 Dec; 128(6 Suppl):642S-646S. PubMed ID: 16373886
[No Abstract] [Full Text] [Related]
20. Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension.
Yamanaka R; Otsuka F; Nakamura K; Yamashita M; Otani H; Takeda M; Matsumoto Y; Kusano KF; Ito H; Makino H
Hypertens Res; 2010 May; 33(5):435-45. PubMed ID: 20186146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
